People · Operator
Named in public records as an officer, director or promoter · active 2024–2024 · Biotech / Pharma, Other Technology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Q Bio, Inc. | — | Biotech / Pharma | Series B | $27.1M | $213.8M | 2024 |
| Proof of Impact, Inc. | — | Other Technology | Pre-Seed | $570K | $3.4M | 2024 |
Jeffrey Kaditz at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Jeffrey Kaditz on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Chadd Evans | 1 | 27 |
| Terry Doyle | 1 | 1 |
| Vijay Pande, Ph.D. | 1 | 1 |
| Clarissa Shen | 1 | 1 |
| Fleur Heyns | 1 | 1 |
| Oskar Miel | 1 | 1 |
| Karl Kleissner | 1 | 1 |
| Kevin Farrelly | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.